Overview
Kasabach-Merritt syndrome (KMS) is characterized by the association of large, rapidly growing vascular tumors with thrombocytopenia and a hemorrhagic diathesis 12.Diagnosis
Presence of vascular tumors (often tufted angiomas) 1
Thrombocytopenia with evidence of platelet consumption 12
Hemorrhagic manifestations such as petechiae and bleeding 12
Immunohistochemical confirmation of platelet trapping within tumor vasculature using markers like CD61 1Management
Aggressive supportive care including platelet transfusions to manage bleeding 2
Surgical intervention may be considered for tumor resection if feasible 2
Anticoagulation or thrombolytic therapy is generally avoided due to risk of hemorrhage 2
Specific drug doses not detailed in provided abstractsSpecial Populations
Pediatrics: KMS predominantly affects infants and young children, highlighting the critical need for early intervention 12Key Recommendations
Confirm diagnosis through clinical presentation and immunohistochemical evidence of platelet trapping within vascular tumors (Evidence: Moderate) 1
Prioritize supportive care with platelet transfusions to manage thrombocytopenia and associated bleeding risks (Evidence: Expert opinion) 2
Consider surgical resection of the vascular tumor if it is feasible and safe, given the potential for life-threatening coagulopathy (Evidence: Expert opinion) 2References
1 Seo SK, Suh JC, Na GY, Kim IS, Sohn KR. Kasabach-Merritt syndrome: identification of platelet trapping in a tufted angioma by immunohistochemistry technique using monoclonal antibody to CD61. Pediatric dermatology 1999. link
2 Maceyko RF, Camisa C. Kasabach-Merritt syndrome. Pediatric dermatology 1991. link